Pfenex Inc. (PFNX) 15.80 $PFNX
Pfenex Inc. Announces Pricing Of Follow-on Offering
PR Newswire - Fri Apr 24, 7:30AM CDT
Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today announced the pricing of its follow-on public offering of 6,000,000 shares of its common stock at a price to the public of $15.50 per share. Of the shares being offered, 2,610,000 are being offered by Pfenex and the remaining 3,390,000 shares are being offered by existing stockholders. Pfenex will not receive any proceeds from the shares sold by existing stockholders. In addition, the underwriters have a 30-day option to purchase up to 750,000 additional shares of common stock from certain existing stockholders.
PFNX: 15.80 (-0.20)
Pfenex Inc. Shifts Focus In-House To Develop Biosimilar To Betaseron
Christopher Stoehr - at Seeking Alpha - Wed Apr 22, 11:10AM CDT
PFE: 35.27 (-0.09), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05)
Pfenex Inc. - Product Pipeline Review - 2014
M2 - Mon Apr 20, 4:03AM CDT
Product Pipeline Review - 2014
PFNX: 15.80 (-0.20)
Insys Therapeutics Inc. Poised For Strong Growth In Earnings Ahead
Christopher Stoehr - at Seeking Alpha - Wed Apr 01, 7:43AM CDT
INSY: 62.42 (-1.90), GWPH: 121.00 (+0.23), PFNX: 15.80 (-0.20)
Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT
EPRS: 8.67 (-0.10), PFNX: 15.80 (-0.20), CHRS: 23.52 (-0.88)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 11:45AM CDT
ABMD: 68.83 (-0.74), WLL: 35.62 (-1.01), NEON: 4.56 (-0.16), JRJC: 5.59 (+0.08), OVAS: 30.40 (-0.55), HPJ: 4.33 (+0.09), ISR: 1.50 (-0.02), DPLO: 36.71 (+0.46), MDVX: 4.00 (+0.05), SONS: 8.46 (+0.53), SLTD: 4.54 (+0.14), PFNX: 15.80 (-0.20), CSUN: 2.01 (-0.04), EARS: 4.78 (-0.17), SEED: 1.77 (+0.16), ORMP: 7.45 (+0.08), ESSX: 1.27 (-0.04), FPP: 1.69 (+0.46), DGLY: 13.88 (+0.39), ZAGG: 8.94 (-0.25)
Pfenex to receive $51M payment from Hospira for Lucentis biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 11:38AM CDT
PFE: 35.27 (-0.09), PFNX: 15.80 (-0.20)
Pfenex Announces Early HSR Clearance for Collaboration with Hospira
PR Newswire - Mon Mar 23, 8:00AM CDT
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive collaboration agreement executed by the company on February 9, 2014 with Hospira, Inc. to develop and commercialize, PF582, Pfenex's biosimilar product candidate to Genentech's LUCENTIS® (ranibizumab injection).
PFNX: 15.80 (-0.20)
Pfenex's (PFNX) CEO, Bert Liang on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 10:10AM CDT
PFNX: 15.80 (-0.20)
Pfenex beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:32AM CDT
PFNX: 15.80 (-0.20)
Pfenex Reports Fourth Quarter and Full Year 2014 Results and Provides Business Update
PR Newswire - Mon Mar 16, 7:30AM CDT
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2014 and provided a business update.
PFNX: 15.80 (-0.20)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), VRTX: 133.20 (-2.62), CERU: 6.27 (+0.07), FOMX: 10.46 (-0.44), ONTX: 2.34 (-0.05), PFNX: 15.80 (-0.20), OMER: 24.32 (-0.35), PGNX: 6.03 (-0.38), SYN: 2.33 (+0.01), VCYT: 9.63 (+0.40), STEM: 0.61 (-0.21), APRI: 1.61 (-0.13), KPTI: 31.49 (-1.13)
FDA clears first biosimilar
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:12AM CST
ESPR: 104.60 (-4.29), AMGN: 167.91 (-1.26), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 35.27 (-0.09), OPHT: 52.15 (+0.17), GSK: 46.59 (+0.28), PFNX: 15.80 (-0.20), LPTN: 2.23 (-0.01), AGN: 240.22 (+2.88), AAVL: 37.57 (-0.92), OHRP: 2.94 (+0.12), NVS: 104.28 (-1.22)
Pfenex to Present at the 2015 Barclays Global Healthcare Conference
PR Newswire - Mon Mar 02, 7:30AM CST
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at the 2015 Barclays Global Healthcare Conference in Miami, FL at the Loews Miami Beach Hotel. Dr. Bert Liang, chief executive officer of Pfenex, will provide an overview of the company's development programs and business strategy on March 12th at 9:00 am ET. A live audio webcast and archive of the presentation will be available in the Investor Relations section of the Pfenex website at www.pfenex.com.
PFNX: 15.80 (-0.20)
Why I Believe Pfenex Is A Strong Buy
Christopher Stoehr - at Seeking Alpha - Sat Feb 28, 5:15AM CST
PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), MDT: 77.61 (-0.89), XON: 44.10 (-0.91), CTIC: 1.96 (+0.01), PFNX: 15.80 (-0.20), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), NVAX: 8.58 (-0.07), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82), TBPH: 18.39 (+0.06), SNY: 51.75 (-0.01), ALQA: 4.96 (+0.16), REGN: 480.09 (+0.01), ONCY: 0.75 (-0.05), PFE: 35.27 (-0.09), SLXP: 172.96 (+0.15), EPRS: 8.67 (-0.10), AMGN: 167.91 (-1.26), NKTR: 10.77 (-0.29), ZTS: 47.91 (+0.86), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), GERN: 4.30 (-0.03)
Pfenex to Present at the 2015 RBC Capital Markets' Healthcare Conference
PR Newswire - Fri Feb 13, 7:30AM CST
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at the 2015 RBC Capital Markets' Healthcare Conference in New York at the New York Palace Hotel. Dr. Bert Liang, chief executive officer of Pfenex, will provide an overview of the company's development programs and business strategy on February 25th at 3:05 pm ET. A live audio webcast and archive of the presentation will be available in the Investor Relations section of the Pfenex website at www.pfenex.com.
PFNX: 15.80 (-0.20)
Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST
JNJ: 101.08 (+0.62), PFE: 35.27 (-0.09), AMGN: 167.91 (-1.26), EPRS: 8.67 (-0.10), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05), NVS: 104.28 (-1.22), CHRS: 23.52 (-0.88)
Pfenex Up on Lucentis Biosimilar Collaboration with Hospira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 11:30AM CST
Hospira (HSP) inked a deal with Pfenex Inc. (PFNX) for the development and global commercialization of PF582, a biosimilar of Lucentis (eye treatment).
ABAX: 63.62 (+0.31), PFE: 35.27 (-0.09), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05)
Pfenex Inc. Announces Pricing Of Follow-on Offering
PR Newswire - Fri Apr 24, 7:30AM CDT
Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today announced the pricing of its follow-on public offering of 6,000,000 shares of its common stock at a price to the public of $15.50 per share. Of the shares being offered, 2,610,000 are being offered by Pfenex and the remaining 3,390,000 shares are being offered by existing stockholders. Pfenex will not receive any proceeds from the shares sold by existing stockholders. In addition, the underwriters have a 30-day option to purchase up to 750,000 additional shares of common stock from certain existing stockholders.
PFNX: 15.80 (-0.20)
Pfenex Inc. Shifts Focus In-House To Develop Biosimilar To Betaseron
Christopher Stoehr - at Seeking Alpha - Wed Apr 22, 11:10AM CDT
PFE: 35.27 (-0.09), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05)
Pfenex Inc. - Product Pipeline Review - 2014
M2 - Mon Apr 20, 4:03AM CDT
Product Pipeline Review - 2014
PFNX: 15.80 (-0.20)
Insys Therapeutics Inc. Poised For Strong Growth In Earnings Ahead
Christopher Stoehr - at Seeking Alpha - Wed Apr 01, 7:43AM CDT
INSY: 62.42 (-1.90), GWPH: 121.00 (+0.23), PFNX: 15.80 (-0.20)
Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT
EPRS: 8.67 (-0.10), PFNX: 15.80 (-0.20), CHRS: 23.52 (-0.88)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 11:45AM CDT
ABMD: 68.83 (-0.74), WLL: 35.62 (-1.01), NEON: 4.56 (-0.16), JRJC: 5.59 (+0.08), OVAS: 30.40 (-0.55), HPJ: 4.33 (+0.09), ISR: 1.50 (-0.02), DPLO: 36.71 (+0.46), MDVX: 4.00 (+0.05), SONS: 8.46 (+0.53), SLTD: 4.54 (+0.14), PFNX: 15.80 (-0.20), CSUN: 2.01 (-0.04), EARS: 4.78 (-0.17), SEED: 1.77 (+0.16), ORMP: 7.45 (+0.08), ESSX: 1.27 (-0.04), FPP: 1.69 (+0.46), DGLY: 13.88 (+0.39), ZAGG: 8.94 (-0.25)
Pfenex to receive $51M payment from Hospira for Lucentis biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 11:38AM CDT
PFE: 35.27 (-0.09), PFNX: 15.80 (-0.20)
Pfenex Announces Early HSR Clearance for Collaboration with Hospira
PR Newswire - Mon Mar 23, 8:00AM CDT
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive collaboration agreement executed by the company on February 9, 2014 with Hospira, Inc. to develop and commercialize, PF582, Pfenex's biosimilar product candidate to Genentech's LUCENTIS® (ranibizumab injection).
PFNX: 15.80 (-0.20)
Pfenex's (PFNX) CEO, Bert Liang on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 10:10AM CDT
PFNX: 15.80 (-0.20)
Pfenex beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:32AM CDT
PFNX: 15.80 (-0.20)
Pfenex Reports Fourth Quarter and Full Year 2014 Results and Provides Business Update
PR Newswire - Mon Mar 16, 7:30AM CDT
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2014 and provided a business update.
PFNX: 15.80 (-0.20)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.05), VRTX: 133.20 (-2.62), CERU: 6.27 (+0.07), FOMX: 10.46 (-0.44), ONTX: 2.34 (-0.05), PFNX: 15.80 (-0.20), OMER: 24.32 (-0.35), PGNX: 6.03 (-0.38), SYN: 2.33 (+0.01), VCYT: 9.63 (+0.40), STEM: 0.61 (-0.21), APRI: 1.61 (-0.13), KPTI: 31.49 (-1.13)
FDA clears first biosimilar
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:12AM CST
ESPR: 104.60 (-4.29), AMGN: 167.91 (-1.26), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 35.27 (-0.09), OPHT: 52.15 (+0.17), GSK: 46.59 (+0.28), PFNX: 15.80 (-0.20), LPTN: 2.23 (-0.01), AGN: 240.22 (+2.88), AAVL: 37.57 (-0.92), OHRP: 2.94 (+0.12), NVS: 104.28 (-1.22)
Pfenex to Present at the 2015 Barclays Global Healthcare Conference
PR Newswire - Mon Mar 02, 7:30AM CST
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at the 2015 Barclays Global Healthcare Conference in Miami, FL at the Loews Miami Beach Hotel. Dr. Bert Liang, chief executive officer of Pfenex, will provide an overview of the company's development programs and business strategy on March 12th at 9:00 am ET. A live audio webcast and archive of the presentation will be available in the Investor Relations section of the Pfenex website at www.pfenex.com.
PFNX: 15.80 (-0.20)
Why I Believe Pfenex Is A Strong Buy
Christopher Stoehr - at Seeking Alpha - Sat Feb 28, 5:15AM CST
PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), MDT: 77.61 (-0.89), XON: 44.10 (-0.91), CTIC: 1.96 (+0.01), PFNX: 15.80 (-0.20), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), NVAX: 8.58 (-0.07), SHPG: 255.11 (-0.26), ABBV: 66.07 (+1.82), TBPH: 18.39 (+0.06), SNY: 51.75 (-0.01), ALQA: 4.96 (+0.16), REGN: 480.09 (+0.01), ONCY: 0.75 (-0.05), PFE: 35.27 (-0.09), SLXP: 172.96 (+0.15), EPRS: 8.67 (-0.10), AMGN: 167.91 (-1.26), NKTR: 10.77 (-0.29), ZTS: 47.91 (+0.86), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), GERN: 4.30 (-0.03)
Pfenex to Present at the 2015 RBC Capital Markets' Healthcare Conference
PR Newswire - Fri Feb 13, 7:30AM CST
Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, today announced that it will be presenting at the 2015 RBC Capital Markets' Healthcare Conference in New York at the New York Palace Hotel. Dr. Bert Liang, chief executive officer of Pfenex, will provide an overview of the company's development programs and business strategy on February 25th at 3:05 pm ET. A live audio webcast and archive of the presentation will be available in the Investor Relations section of the Pfenex website at www.pfenex.com.
PFNX: 15.80 (-0.20)
Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST
JNJ: 101.08 (+0.62), PFE: 35.27 (-0.09), AMGN: 167.91 (-1.26), EPRS: 8.67 (-0.10), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05), NVS: 104.28 (-1.22), CHRS: 23.52 (-0.88)
Pfenex Up on Lucentis Biosimilar Collaboration with Hospira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 11:30AM CST
Hospira (HSP) inked a deal with Pfenex Inc. (PFNX) for the development and global commercialization of PF582, a biosimilar of Lucentis (eye treatment).
ABAX: 63.62 (+0.31), PFE: 35.27 (-0.09), PFNX: 15.80 (-0.20), HSP: 87.61 (-0.05)
